Affinia Therapeutics Publicizes the Appointment of Rami Daoud as Chief Business and Monetary Officer By Investing.com

Trade veteran Daoud brings greater than 25 years’ expertise in enterprise improvement and company finance and technique at a number of main biopharmaceutical organizations

WALTHAM,  Mass., Sept. 10, 2024 /PRNewswire/ — Affinia  Therapeutics (“Affinia”),  an  revolutionary  firm with a proprietary platform pioneering a shift to a brand new class of rationally-designed gene  therapies  for  uncommon  and  prevalent devastating illnesses,  at this time  introduced the appointment of Rami Daoud, M.B.A., as Chief Business and Monetary Officer.

“Affinia is delighted to welcome Rami as our Chief Business and Financial Officer,” stated Rick Modi, Affinia’s Chief Govt Officer. “Rami is a seasoned biopharma executive with a successful track record in business development and biotech finance and corporate strategy. His expertise will be instrumental as we advance our innovative platform and pipeline of rationally designed gene therapies for devastating cardiovascular and neurological diseases toward the clinic.”

Rami is an completed biopharmaceutical enterprise govt who’s captivated with bringing to market revolutionary therapeutics aimed toward saving lives and bettering the well being and well-being of sufferers globally. He has greater than 25 years’ skilled and senior management expertise working at giant pharmaceutical and biotech firms in each private and non-private sectors together with Amarin (NASDAQ:) Company, Auxilium Prescribed drugs, Eli Lilly (NYSE:) & Firm, and Human Genome Sciences. Rami has deep experience throughout varied therapeutic areas and commercialization fashions, and a profitable observe file of deal making and main strategic initiatives globally within the U.S., Europe, Japan, China and different rising markets.

Mr. Daoud stated, “I am thrilled to join the team at Affinia with its validated leading-edge rationally designed gene therapy platform and exciting cardiovascular and neurological disease pipeline  and the opportunities ahead. I look forward to contributing my expertise in business development and corporate finance and strategy to advance Affinia’s strategic priorities so that we can help patients in areas of high unmet medical need.”

Previous to becoming a member of Affinia, Rami was President of GeneSciences Prescribed drugs USA. Earlier than GeneSciences, Rami spent eight years at Amarin Company as a Senior Vice President of Company Growth and a member of its govt administration staff. Beforehand, Rami held enterprise improvement and technique roles with escalating duties at Auxilium Prescribed drugs (offered to Endo), ACEA Biosciences (offered to Agilent Applied sciences (NYSE:)), TransForm Prescribed drugs (offered to Johnson & Johnson (NYSE:)), and Eli Lilly & Firm. He began his profession as a analysis scientist initially on the Nationwide Institutes of Well being previous to becoming a member of business at Human Genome Sciences. Rami holds an M.B.A from the Wharton Faculty, an M.S. in physiology from the College of Maryland at Baltimore, and a B.S. in accounting and B.S. in biology from the College of Maryland.

About  Affinia Therapeutics
Affinia Therapeutics is pioneering a shift to a brand new class of rationally-designed gene therapies that deal with uncommon and prevalent illnesses. Affinia Therapeutics’ proprietary Affinia Rationally-designed Therapeutics (ART) platform is meant to synergistically enhance the efficacy, security, and manufacturability of adeno-associated virus (AAV)-based gene therapies via the event of next-generation capsids, promoters, and manufacturing approaches. For extra info, go to https://www.affiniatx.com.